

Medicines and Poisons Act 2019

Extended Practice Authority 'Pharmacists – Community pharmacy scope of practice pilot'



Queensland Government

Version control

Version	Replaces version	Date approved	Commencement date
2	1	20 May 2024	1 July 2024

Disclaimer: Please note that any material printed is regarded as an uncontrolled copy. It is the responsibility of the person printing the document to refer frequently to <https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines-poisons-act/legislation-standards> for updates

Extended Practice Authority - 'Community Pharmacy Scope of Practice Pilot'

This extended practice authority (EPA) has been made by the Director-General, Queensland Health, as the chief executive under section 232 of the *Medicines and Poisons Act 2019* (Qld). It states the scope of the regulated activities with the regulated substances which a participating pharmacist is authorised to carry out for the purposes described in the table under Schedule 9, Part 1 of the Medicines and Poisons (Medicines) Regulation 2021 (Qld).

A term used in this EPA that is defined in the *Medicines and Poisons Act 2019* or the Medicines and Poisons (Medicines) Regulation 2021, has the meaning stated in the *Medicines and Poisons Act 2019* or Medicines and Poisons (Medicines) Regulation 2021.

Part 1. Circumstances and conditions

1. A participating pharmacist must meet the requirements specified within the "Queensland Community Pharmacy Scope of Practice Pilot – Participation Requirements" to dispense, prescribe, or sell a medicine under this EPA.
2. A participating pharmacist may only dispense, prescribe, or sell a medicine under this EPA in a participating pharmacy that meets the requirements specified within the "Queensland Community Pharmacy Scope of Practice Pilot – Participation Requirements".
3. A participating pharmacist must not dispense, sell or prescribe a medicine for the treatment of an animal under this EPA.
4. A participating pharmacist must, when dispensing, prescribing or selling a medicine under this EPA, keep a clinical record in accordance with relevant legislative and professional responsibilities, and detailing consent of the patient and additional requirements as stated in Parts 2, 3 and 4 of this EPA.

Part 2. Amending and dispensing a prescription

5. A participating pharmacist may amend a medicine stated on a prescription (***the original medicine***) only in circumstances where the amendment is necessary to meet the clinical need of the patient.
 - 5.1. In making this determination the participating pharmacist must consider the following:
 - 5.1.1. Whether the patient circumstances are likely to limit the intended therapeutic effect of the original medicine; and/or
 - 5.1.2. Whether an amendment to the original medicine is necessary to allow the continuation of therapeutic treatment.
6. A participating pharmacist may amend a medicine stated on a prescription by substituting the original medicine on the prescription for another medicine where the participating pharmacist is satisfied the substituted medicine:
 - 6.1. Belongs to the same therapeutic class as the original medicine; and
 - 6.2. Has an equivalent pharmacologic mechanism of action to the original medicine; and
 - 6.3. Has the same approved indication as the original medicine; and

- 6.4. Has an established equivalent therapeutic effect to the original medicine, accounting for any required variation in dose or directions.
7. If the original medicine stated on the prescription is amended, the total amount of medicine dispensed by the participating pharmacist under this EPA must be of an equivalent duration and/or dosage regimen as that specified on the prescription for the original medicine.
8. A participating pharmacist may only make the amendment for a single dispensing episode only.
9. A participating pharmacist must not amend any subsequent repeats for the prescription that contains the original medicine.
10. If the original medicine stated on the prescription is amended when dispensing a medicine under this EPA, the participating pharmacist must include the following information within the clinical record:
 - 10.1. The reason for the amendment; and
 - 10.2. The amendments made, including the name of the medicine as well as the form, strength, amount and instructions for use of the medicine.

Part 3. Selling an S4 medicine

11. A participating pharmacist may sell a medicine to a patient under this EPA for the purposes of continuing therapeutic treatment where:
 - 11.1. The medicine has been previously prescribed to the patient; and
 - 11.2. Continuing the patient's treatment with the medicine is urgent and essential for the patient's wellbeing; and
 - 11.3. It is not practicable for the patient to obtain a prescription for the medicine before it is needed to continue treatment; and
 - 11.4. The medicine has been supplied to the patient within six (6) months before the medicine is sought from the participating pharmacist; and
 - 11.5. The patient has not, in the year before seeking the medicine from the participating pharmacist, been sold the medicine without a prescription; and
 - 11.6. The participating pharmacist has determined the condition that is being treated by the medicine is stable and it is safe and appropriate to sell the medicine.
12. A participating pharmacist must sell the smallest available size of a manufacturer's pack of the medicine.
13. When selling a medicine under this EPA, the participating pharmacist must include the following within the clinical record:
 - 13.1. The reasons for selling the medicine including considerations for clinical decision making; and
 - 13.2. The name of the medicine as well as the form, strength, amount and instructions for use of the medicine.

Part 4. Prescribing

14. A participating pharmacist may only prescribe a medicine listed in Appendix 1 Column 1, subject to the specifications in Column 3 and the indications stated in Column 2, in accordance with the relevant restrictions in Column 4.
15. A participating pharmacist must, when prescribing a medicine under this EPA, fully document the following in the clinical record of a consultation with a patient:
 - 15.1. Relevant patient history, and
 - 15.2. An assessment of the condition that requires the prescribed medicine; and
 - 15.3. The management plan for treating the patient's condition including:
 - 15.3.1. The name of the medicine prescribed; and
 - 15.3.2. The strength of the medicine prescribed; and
 - 15.3.3. The formulation of the medicine prescribed; and
 - 15.3.4. The instructions for use of the medicine prescribed; and
 - 15.3.5. The amount of the medicine prescribed.
16. The participating pharmacist must, when prescribing a medicine under this EPA, conduct the recommended clinical assessment and management of the indication in accordance with the relevant Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline or Clinical Protocol.

Appendix 1. Medicines for the Pilot

Column 1 — Regulated substance	Column 2 — Indication	Column 3 — Therapeutic Guideline section reference	Column 4 — Restrictions
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Acute exacerbations of mild plaque psoriasis	<ul style="list-style-type: none">• Dermatology: Psoriasis	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled "Acute exacerbations of mild plaque psoriasis"
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Acute minor wound management	<ul style="list-style-type: none">• Antibiotic: Traumatic wound infections• Pain and analgesia: Drugs used for pain: Local anaesthetics for acute pain management	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled "Acute minor wound management"

Column 1 — Regulated substance	Column 2 — Indication	Column 3 — Therapeutic Guideline section reference	Column 4 — Restrictions
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Acute nausea and vomiting	<ul style="list-style-type: none"> Gastrointestinal: Nausea and vomiting 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Acute nausea and vomiting”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Acute otitis externa	<ul style="list-style-type: none"> Antibiotic: Ear, nose and throat infections: Otitis externa Pain and Analgesia: Pharmacological management of acute pain 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Acute otitis externa”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Acute otitis media	<ul style="list-style-type: none"> Antibiotic: Ear, nose and throat infections: Otitis media Pain and Analgesia: Pharmacological management of acute pain 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Acute otitis media”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Allergic and nonallergic rhinitis	<ul style="list-style-type: none"> Respiratory: Rhinitis and rhinosinusitis 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Allergic and nonallergic rhinitis”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Gastro-oesophageal reflux and gastro-oesophageal reflux disease	<ul style="list-style-type: none"> Gastrointestinal: Oesophageal disorders: Gastro-oesophageal reflux in adults 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Gastro-oesophageal reflux and gastro-oesophageal reflux disease”

Column 1 — Regulated substance	Column 2 — Indication	Column 3 — Therapeutic Guideline section reference	Column 4 — Restrictions
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Herpes zoster (shingles)	<ul style="list-style-type: none"> • Antibiotic: Skin and soft tissue infections: Shingles • Pain and analgesia: Managing specific pain syndromes: Pain associated with shingles (herpes zoster) • Pain and analgesia: Pharmacological management of acute pain 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Herpes zoster (shingles)”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Impetigo	<ul style="list-style-type: none"> • Antibiotic: Skin and soft tissue infections: Impetigo 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Impetigo”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Management for overweight and obesity	<ul style="list-style-type: none"> • Cardiovascular: Modifiable lifestyle risk factors for atherosclerotic cardiovascular disease 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Management for overweight and obesity”

Column 1 — Regulated substance	Column 2 — Indication	Column 3 — Therapeutic Guideline section reference	Column 4 — Restrictions
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Mild, acute musculoskeletal pain	<ul style="list-style-type: none"> • Pain and analgesia: Pharmacological management of acute pain • Rheumatology: Principles of analgesic and anti-inflammatory drug use for musculoskeletal conditions in adults: Principles of nonsteroidal anti-inflammatory drug use for musculoskeletal conditions in adults 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Mild, acute musculoskeletal pain”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Mild to moderate acne	<ul style="list-style-type: none"> • Dermatology: Acne 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Mild to moderate acne”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Mild to moderate atopic dermatitis	<ul style="list-style-type: none"> • Dermatology: Dermatitis: Atopic dermatitis 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Mild to moderate atopic dermatitis”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Oral health risk assessment and fluoride application	<ul style="list-style-type: none"> • Oral and Dental: Dental caries 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled “Oral health risk assessment and fluoride application”

Column 1 — Regulated substance	Column 2 — Indication	Column 3 — Therapeutic Guideline section reference	Column 4 — Restrictions
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Smoking cessation	<ul style="list-style-type: none"> Addiction: Tobacco smoking and nicotine dependence 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled "Smoking cessation"
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Travel health	<ul style="list-style-type: none"> Antibiotic: Acute infectious diarrhoea: Travellers' diarrhoea Antibiotic: Parasitic infections: Malaria Gastrointestinal: Acute gastroenteritis Gastrointestinal: Nausea and vomiting Wilderness Medicine: Altitude illness 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled "Travel health"
Rabies vaccine	Travel health	n/a	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Practice Guideline titled "Travel health"
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Chronic obstructive pulmonary disease (COPD)	<ul style="list-style-type: none"> Respiratory: Chronic obstructive pulmonary disease (COPD) 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Protocol titled "Chronic obstructive pulmonary disease (COPD) monitoring program"

Column 1 — Regulated substance	Column 2 — Indication	Column 3 — Therapeutic Guideline section reference	Column 4 — Restrictions
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Cardiovascular disease risk reduction	<ul style="list-style-type: none"> • Cardiovascular: Blood pressure reduction: Hypertension and blood pressure reduction • Cardiovascular: Lipid modification • Diabetes: Type 2 diabetes in adults 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Protocol titled “Cardiovascular disease (CVD) risk reduction program”
A medicine mentioned in the current online version of the Therapeutic Guidelines within the section specified in Column 3 for the management of the indication listed in Column 2	Asthma	<ul style="list-style-type: none"> • Respiratory: Asthma 	The medicine is prescribed in accordance with the Queensland Community Pharmacy Scope of Practice Pilot Clinical Protocol titled “Improved asthma symptom control program”